Hsa-miR-223-3p participates in the process of anthracycline-induced cardiomyocyte damage by regulating NFIA gene

Abstract Irreversible cardiomyopathy was caused by the therapeutic of anthracyclines in the chemotherapy of cancers. The cell apoptosis and autophagy were induced by anthracyclines in AC16 cells. MiR-223-3p ascends in anthracycline-treated AC16, but the expression of nuclear factor I-A (NFIA) was specifically down-regulated. However, the underlying molecular mechanism between NFIA and miR-223-3p is unclear now in AC16 cells. In our research, NFIA expression was dampened in AC16 cells by miR-223-3p mimics. Additionally, miR-223-3p knockdown hindered the apoptosis and autophagy in anthracycline-treated AC16. Furthermore, NFIA was predicted and verified as a miR-223-3p’s downstream target and rescued the functions of miR-223-3p. These findings illustrated that miR-223-3p advances anthracycline-stimulated cardiomyocyte damage progression by targeting NFIA, implying the promising therapeutic function of miR-223-3p on cardiomyocyte damage in cancer patients.

[1]  C. Tiribelli,et al.  The role of microRNA in the resistance to treatment of hepatocellular carcinoma. , 2019, Annals of translational medicine.

[2]  Wei Zhu,et al.  MiR-212-3p inhibits cell proliferation and promotes apoptosis by targeting nuclear factor IA in bladder cancer , 2019, Journal of Biosciences.

[3]  J. Blanco,et al.  Insights into the transcriptional regulation of the anthracycline reductase AKR7A2 in human cardiomyocytes. , 2019, Toxicology letters.

[4]  Ming-yue Li,et al.  Absence of miR‐223‐3p ameliorates hypoxia‐induced injury through repressing cardiomyocyte apoptosis and oxidative stress by targeting KLF15 , 2018, European journal of pharmacology.

[5]  L. Skálová,et al.  MicroRNAs in the diagnosis and prevention of drug-induced cardiotoxicity , 2018, Archives of Toxicology.

[6]  Peng Li,et al.  Prognostic significance of NFIA and NFIB in esophageal squamous carcinoma and esophagogastric junction adenocarcinoma , 2018, Cancer medicine.

[7]  W. Maloney,et al.  miR-223-3p Inhibits Human Osteosarcoma Metastasis and Progression by Directly Targeting CDH6 , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

[8]  Bo-yu Xue,et al.  miRNA-223-3p regulates NLRP3 to promote apoptosis and inhibit proliferation of hep3B cells , 2017, Experimental and therapeutic medicine.

[9]  C. Shih,et al.  The microRNA-302b-inhibited insulin-like growth factor-binding protein 2 signaling pathway induces glioma cell apoptosis by targeting nuclear factor IA , 2017, PloS one.

[10]  D. Yellon,et al.  Anthracycline Chemotherapy and Cardiotoxicity , 2017, Cardiovascular Drugs and Therapy.

[11]  E. Hoxha,et al.  A novel NFIA-NF&kgr;B feed-forward loop contributes to glioblastoma cell survival , 2016, Neuro-oncology.

[12]  C. Larsson,et al.  miR-223-3p regulates cell growth and apoptosis via FBXW7 suggesting an oncogenic role in human testicular germ cell tumors , 2016, International journal of oncology.

[13]  Miki Ohira,et al.  Recent trends in microRNA research into breast cancer with particular focus on the associations between microRNAs and intrinsic subtypes , 2016, Journal of Human Genetics.

[14]  Chaoqian Xu,et al.  MiR-223-3p as a Novel MicroRNA Regulator of Expression of Voltage-Gated K+ Channel Kv4.2 in Acute Myocardial Infarction , 2016, Cellular Physiology and Biochemistry.

[15]  E. Saleh,et al.  Epigenetics and miRNA as predictive markers and targets for lung cancer chemotherapy , 2015, Cancer biology & therapy.

[16]  P. Duan,et al.  miR-29a activates Hes1 by targeting Nfia in esophageal carcinoma cell line TE-1 , 2014, Oncology letters.

[17]  Stephen T. C. Wong,et al.  The miR-223/Nuclear Factor I-A Axis Regulates Glial Precursor Proliferation and Tumorigenesis in the CNS , 2013, The Journal of Neuroscience.

[18]  H. Hermeking,et al.  MicroRNA-34a regulates cardiac ageing and function , 2013, Nature.

[19]  K. Chowdhury,et al.  The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy , 2012, Nature Communications.

[20]  O. Kent,et al.  A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes , 2006, Oncogene.

[21]  L. Gianni,et al.  Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity , 2004, Pharmacological Reviews.

[22]  V. Ambros,et al.  The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14 , 1993, Cell.

[23]  R. J. Cersosimo,et al.  Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.